<i>ERBB3</i> -altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities.
Steven Blinka(Fred Hutch Cancer Center), Petros Grivas(University of Washington), A. Kamat(The University of Texas MD Anderson Cancer Center), R. Graf(Foundation Medicine (United States)), Ruben Raychaudhuri(University of Washington), Sumanta Kumar Pal(City Of Hope National Medical Center), J L Lortat Jacob(SUNY Upstate Medical University), Andrea Necchi(Vita-Salute San Raffaele University), Gennady Bratslavsky(SUNY Upstate Medical University), Philippe E. Spiess(Moffitt Cancer Center), Jeffrey S. Ross(SUNY Upstate Medical University), Roger Li(Moffitt Cancer Center), Rosa Nadal(University of Washington), Shilpa Gupta(Cleveland Clinic), Dean C. Pavlick(Foundation Medicine (United States)), Alina Basnet(Cancer Clinic), Neeraj Agarwal(University of Utah)
Cited by 0
Related Papers
Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis
|Oncotarget|2018|15
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
|Journal of Clinical Oncology|2024|1